Bégaud Evelyne, Feindirongai Gilbert, Versmisse Pierre, Ipero Julienne, Léal Josiane, Germani Yves, Morvan Jacques, Fleury Hervé, Müller-Trutwin Michaela, Barré-Sinoussi Françoise, Pancino Gianfranco
Institute Pasteur, Bangui, Central Africa Republic.
AIDS Res Hum Retroviruses. 2003 Jul;19(7):551-60. doi: 10.1089/088922203322230914.
To study the progression of HIV-1 infection and coreceptor usages in Central African Republic, clinical data, plasma viral load, and coreceptor usage of sequential HIV-1 isolates were analyzed in a seroincident prospective cohort (PRIMOCA). Twenty-three HIV-1 infected individuals from the Central African Armed Forces were followed from 1995 to 2000. Viruses were isolated from 17 patients at various time points after seroconversion and their coreceptor usage was examined using GHOST cells expressing CD4 and one of the HIV-1 chemokine coreceptors CCR5, CXCR4, BOB/GPR15, and Bonzo/STRL33/CXCR6. Eleven patients died from AIDS. Eight of them died between 2 and 5 years after seroconversion, after a brief symptomatic stage. Patients who rapidly progressed to AIDS and death displayed the highest viral loads after seroconversion. All isolates obtained soon after seroconversion used CCR5, albeit, in some cases, CXCR4, BOB, or Bonzo were also used. Most isolates remained R5 (59 out of 61 isolates), although viruses using CXCR4 appeared in some cases of progression to AIDS. In several cases, a broad tropism was observed during the course of infection, with a frequent usage of BOB and Bonzo in addition to CCR5. Rapid progression to disease and short survival time among Central African HIV-1 patients appear more frequent than those reported in industrialized countries. Viral coreceptor used was mainly CCR5, but, interestingly, a large part of isolates also used BOB and Bonzo. However, there was no strict correlation between the clinical outcome and extended viral tropism.
为研究中非共和国HIV-1感染的进展及共受体使用情况，我们在一个血清学初发前瞻性队列（PRIMOCA）中分析了连续HIV-1分离株的临床数据、血浆病毒载量及共受体使用情况。对23名来自中非武装部队的HIV-1感染者进行了1995年至2000年的随访。在血清转化后的不同时间点从17名患者中分离出病毒，并使用表达CD4和HIV-1趋化因子共受体之一CCR5、CXCR4、BOB/GPR15和Bonzo/STRL33/CXCR6的GHOST细胞检测其共受体使用情况。11名患者死于艾滋病。其中8人在血清转化后2至5年死亡，此前有一个短暂的症状期。快速进展至艾滋病和死亡的患者在血清转化后病毒载量最高。血清转化后不久获得的所有分离株均使用CCR5，尽管在某些情况下也使用CXCR4、BOB或Bonzo。大多数分离株仍为R5（61株中有59株），尽管在一些进展至艾滋病的病例中出现了使用CXCR4的病毒。在几例病例中，在感染过程中观察到广泛的嗜性，除CCR5外还频繁使用BOB和Bonzo。与工业化国家报告的情况相比，中非HIV-1患者中疾病快速进展和生存时间短的情况似乎更为常见。病毒共受体主要使用CCR5，但有趣的是，很大一部分分离株也使用BOB和Bonzo。然而，临床结果与扩展的病毒嗜性之间没有严格的相关性。
